Ordering
Available Variants100 mg
CHA.44352-100mg
Price
€175.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
100 mg | CHA.44352-100mg | €175.20 |
phyproof® Reference Substance
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C20H26N2O2 |
|---|---|
| CAS Number | 1435-55-8 |
| Molecular Weight | 326.43 |
| NACRES | NA.24 |
| UNSPSC Code | 41116107 |
| Beilstein/REAXYS Number | 91441 |
| MDL number | MFCD00135599 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 |
| pcodes | P264 - P270 - P301 + P312 - P501 |
| Hazard Classifications | Acute Tox. 4 Oral |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
(+)-Dihydroquinidine, with a CAS number of 1435-55-8, is a stereoisomer of dihydroquinidine, exhibiting distinct pharmacological properties. This compound is a derivative of quinidine, a naturally occurring alkaloid found in the bark of the cinchona tree. (+)-Dihydroquinidine has been investigated for its potential therapeutic applications, particularly in the treatment of cardiac arrhythmias. Its mechanism of action involves the blockade of sodium and potassium channels, thereby modulating cardiac conduction and rhythm. As a result, (+)-Dihydroquinidine has been explored as a potential anti-arrhythmic agent, although its clinical use is limited due to its narrow therapeutic index and potential for adverse effects. Further research is necessary to fully elucidate the clinical potential of (+)-Dihydroquinidine and its potential role in the management of cardiac arrhythmias.
